Highly Efficient Antibody Production by Improving Cell Survival Using Sericin

摘要

The antibody therapeutics, as well as the diagnostic market, in Japan has grown rapidly and has soared to an annual total of 55 billion yen. Industrially, these antibodies are produced by fed-batch or perfusion culture of mammalian cells. We have previously reported that sericin improves cell survival, and in this study, we tried to prolong the culture period of the hybridoma cells by supplementing the culture medium with sericin in order to improve monoclonal antibody productivity. In the presence of sericin, maximum cell density and final monoclonal antibody concentration were lower than those in the presence of 0.1% BSA and 10% FBS, but the specific antibody production rate was higher.